Drugs / NPT189
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03879278 | Mar → Jun 2019 | amyloidosis | Proclara Biosciences, Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT03610035 | Jul 2018 → Feb 2019 | amyloidosis | Proclara Biosciences, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NPT189 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03610035 ↗ |
| Modality | Protein / enzyme biologic | “IgG1 Fc-GAIM fusion protein, a recombinant fusion protein” NCT03610035 ↗ |
| Route | Intravenous | “Participants will receive NPT189 by intravenous (IV)” NCT03610035 ↗ |